2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one hydrochloride

• ChemBase编号: 73240
• 分子式: C19H23Cl2N5O
• 平均质量: 408.32482
• 单一同位素质量: 407.12796574
• SMILES: c1ccc(cc1Cl)N1CCN(CC1)CCCn1c(=O)n2c(n1)cccc2.Cl
• Canonical SMILES: Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2.Cl
• InChI: InChI=1S/C19H22ClN5O.ClH/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25;/h1-3,5-7,9,15H,4,8,10-14H2;1H
• InChIKey: OHHDIOKRWWOXMT-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one hydrochloride
• IUPAC传统名: trazodone hydrochloride
• 别名: Bimaran; KB 831; Mesyrel; Molipaxin; Pragmazone; Thombran; Tombran; Trazodone hydrochloride; Trazolan; Trittico; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one hydrochloride; Desyrel; Trazodone hydrochloride; 2-(3-(4-(3-Chlorophenyl)-1-piperazinyl)propyl)-s-triazolo(4,3-a)pyridin-3(2H)-one HCl; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one hydrochloride; Trazodone hydrochloride

登记号

• CAS号: 25332-39-2
• EC号: 246-855-5
• MDL号: MFCD00079603
• PubChem SID: 24278136; 162038160
• PubChem CID: 62935

理论计算性质

• 质子受体: 4
• 质子供体: 0
• LogD (pH = 5.5): 1.5380111
• LogD (pH = 7.4): 2.9594436
• Log P: 3.1318567
• 摩尔折射率: 105.8796 cm^3
• 极化性: 39.210217 Å^3
• 极化表面积: 42.39 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: 0.1 M HCl: soluble7.4 mg/mL; Chloroform; DMSO: soluble; H2O: insoluble; methanol: soluble25 mg/mL
• 外观: light yellow powder; White to Off-White Solid
• 熔点: 223°C; 223-226°C
• 疏水性(logP): 3.85

安全信息

• 保存条件: -20°C; -20°C Freezer; Room Temperature (15-30°C)
• RTECS编号: XZ5660000
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22-40; R:22-36/37/38
• 安全公开号: 22-36; S:25-26-36/37/39
• GHS危险品标识: GHS07; GHS08
• GHS警示词: Warning
• GHS危险声明: H302-H351
• GHS警示性声明: P281
• 个人保护装置: Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges

药理学性质

• 作用靶点: Serotonin receptor
• 相关基因信息: human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2C(3358)

产品相关信息

• 纯度: ≥99% (HPLC); 95%
• 成盐信息: hydrochloride

详细说明

MP Biomedicals - 02191518

Hydrochloride
A serotonin uptake inhibitor.

Selleck Chemicals - S2582

Research Area: Cancer
Biological Activity:
Trazodone hydrochloride (Desyrel) is a hydrochloride salt of trazodone that is a serotonin antagonist and reuptake inhibitor with a Kd of 0.16 μM. Trazodone hydrochloride is a triazolopyridine antidepressant drug. Trazodone is a phenylpiperazine compound. [1][2] Trazodone also has anxiolytic, and hypnotic effects. Trazodone is a psychoactive compound with sedative and anti-depressant properties. Trazodone may also be used for relief of an anxiety disorder (e.g., sleeplessness, tension) and chronic pain. Trazodone behaves as an antagonist at all of the following receptors except 5-HT1A where it acts as a partial agonist similarly to buspirone and tandospirone but with greater intrinsic activity in comparison: 5-HT1A receptor (Kd = 78 nM), 5-HT2A receptor (Ki = 13 nM), 5-HT2C receptor (Ki = 192 nM), α1-adrenergic receptor (Kd = 39 nM), α2-adrenergic receptor (Kd = 405 nM), H1 receptor (Kd = 725 nM). Trazodone acts predominantly as a 5-HT2A receptor antagonist to mediate its therapeutic benefits against anxiety and depression. [3][4] References on Trazodone HCl (Desyrel)[1] http://en.wikipedia.org/wiki/Trazodone, , [2] Psychopharmacology (Berl)., 1992, 109(1-2):2-11[3] J Pharmacol Exp Ther., 1984 Jul, 230(1):94-102[4] Eur J Pharmacol., 1986 Dec 16, 132(2-3):115-21

Sigma Aldrich - T6154

Biochem/physiol Actions
Antidepressant that potentiates the activity of serotonin uptake blockers and has full 5-HT2C serotonin receptor agonist activity. It is metabolized to the 5-HT1 serotonin receptor agonist 1-(3-Chlorophenyl)piperazine.

Toronto Research Chemicals - T718500

Antidepressant.

参考文献

• Wander TJ et al. Eur J Pharmacol. 1986 Dec 16;132(2-3):115-21.
• Silvestrini, B., et al.: Eur. J. Pharmacol., 12, 231 (1970)
• Brogden, R.N., et al.: Drugs, 21, 401 (1970)
• Gorecki, D., et al.: Anal. Profiles Drug Subs., 16, 693 (1970)